Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common stock, par value $0.00001 per share
-
Shares outstanding
-
52,942,731
-
Total 13F shares
-
58,031,251
-
Share change
-
-2,804,797
-
Total reported value
-
$690,573,229
-
Put/Call ratio
-
66%
-
Price per share
-
$11.90
-
Number of holders
-
111
-
Value change
-
-$34,715,020
-
Number of buys
-
62
-
Number of sells
-
37
Institutional Holders of PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) as of Q3 2022
As of 30 Sep 2022 PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) had 111 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 58,031,251 shares of stock of the company.
Largest 10 holders included ORBIMED ADVISORS LLC, JPMORGAN CHASE & CO, RTW INVESTMENTS, LP, STATE STREET CORP, VANGUARD GROUP INC, BlackRock Inc., BOXER CAPITAL, LLC, Avoro Capital Advisors LLC, Euclidean Capital LLC, and RA CAPITAL MANAGEMENT, L.P..
This table shows 112 institutional shareholders of the security as of 30 Sep 2022.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.